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Summary 
In this report we have investigated macrophage (M~b) activity and tumor necrosis  factor 
(TNF-ot) production during graft-vs.-host disease (GVHD). TNF-ot production by M~b requires 
two signals: priming of M~b by interferon followed by triggering of TNF-c~ production and 
release by lipopolysaccharide  (LPS). The state of M~ activation was examined in nonirradiated 
B6AF1 recipient mice injected with either 60  x  106 (acute GVHD) or 30  x  106 (nonlethal 
GVHD) parental B6 lymphoid cells. During the early phase of acute GVHD, administration 
of normally sublethal amounts of LPS-triggered release of significant  amounts of TNF-ot into 
the serum resulting in death of the animals within 36 h. Normal animals treated with the same 
dose of LPS neither died nor produced detectable amounts of serum TNF-ot. In vitro studies 
demonstrated that M~ were primed during GVHD. The level of Mq~ priming was greater during 
acute GVHD than nonlethal GVHD since 100-fold less LPS was required to trigger killing of 
a TNF-ot-sensitive cell line by M~b from acute GVHD animals. The amount of TNF-ot released 
into the serum after LPS injection increased during the course of the GVHD and was significantly 
greater in acute GVH-reactive mice. Endogenous LPS was detected in the serum of acute GVH- 
reactive animals coincident with the onset of mortality. The data provide evidence that during 
GVHD M~b are primed as a result of the allogeneic reaction and that endogenous LPS therefore 
triggers Mq~ production of TNF-c~ resulting in the symptoms characteristic  of acute GVHD. 
G 
VHD remains a major risk factor in allogeneic  bone 
marrow transplantation. The characteristic  features of 
acute GVHD include severe immunosuppression, diarrhea, 
weight loss, and the development of pathologic lesions in 
lymphoid and nonlymphoid tissues (1-7). During the course 
of experimental GVHD, T and B lymphocyte functions are 
suppressed (2, 3, 7), however, macrophages (M~b)  1 are acti- 
vated as demonstrated by an increase in their phagocytic and 
bactericidal  activity (8,  9). 
Two factors,  IFN-3' and LPS, mediate the activation of 
normal M~b in a synergistic manner (10-12). In human bone 
marrow transplant recipients,  an increase in the serum con- 
centration of IFN-'y occurs before clinical manifestation of 
GVHD (13). Indeed a large proportion of the T cell clones 
that can be isolated from such patients produce IFN-'y (14). 
1Abbwviations used in this pa/x,'r: M~b, macrophage(s);  MCS, mouse Con 
A supernatant; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; NRS, normal rabbit  serum;  PFC,  plaque-forming cell. 
During murine GVHD, IFN-'y production has been demon- 
strated by in situ labeling of spleen cells (15) and a decrease 
in the severity of GVHD-associated intestinal lesions after 
treatment of animals with anti-IFN-T (16). LPS, the second 
or triggering signal involved in M~b activation, is an integral 
part of the cell wall of enteric Gram-negative bacteria.  In 
experimental GVHD, the administration of normally non- 
lethal amounts of LPS rapidly results in the onset of shock 
leading to death within 48  h  (17, 18). The symptoms of 
GVHD can be reduced or prevented by germ-free conditions 
or through antibiotic therapy, strongly suggesting that bac- 
terial products are involved in the reaction (19-21). 
Normal M~b exposed to LPS produce and release TNF-ot, 
a protein that has been shown to mediate weight loss or 
cachexia,  some inflammatory processes,  septic  shock, and 
damage to normal and tumor cells (22-27).  Quantities of 
LPS that are insufficient to induce the production and release 
of TNF-ol from normal, unprimed M~b, can trigger IFN- 
"y-primed M~k to produce significant  quantities of TNF-ot 
(12, 28).  In murine GVHD, it has been demonstrated that 
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testinal lesions and mortality (29). More recently, increased 
levels of TNF-ot have been found in the serum of allogeneic 
bone marrow transplant  recipients (30) and have been cor- 
related with  the severity of GVHD  (31,  32). 
To determine whether M~b are the effector cells respon- 
sible for TNF-c~ production during GVHD, we have exam- 
ined the state of M~b activation, response to LPS, and serum 
levels of LPS in nonirradiated F1 hybrid mice injected with 
parental strain lymphoid cells. The results demonstrate that 
during GVHD Mq~ are primed and can release TNF-ot when 
triggered by LPS; that the level of M~b priming and in vivo 
production of serum TNF-ot in response to LPS are related 
to the number of cells transplanted and the time posttrans- 
plant; and that endogenous LPS can be detected in the serum 
during  acute GVHD. 
Materials and Methods 
Mice.  Male  C57BL/6  (B6)  and  C57BL/6  x  AF1  (B6AF1) 
mice were bred and maintained in our laboratory and used at 12-18 
wk of age. 
Reagents and Media.  Recombinant murine TNF-c~ (4  x  104 
U//~g) was purchased from Genzyme Corp. (Boston, MA). LPS 
(Escherichia coli 0111:B4, lot 437627;  Calbiochem Corp., La Jolla, 
CA) was dissolved in PBS and sterilized by irradiation (15,000 tad). 
RPMI 1640, HBSS, PBS (Gibco Laboratories,  Grand Island, NY), 
and FCS (Sterile Systems, Logan, UT) contained <0.25 ng/ml en- 
dotoxin as quantified by the Limulus amebocyte lysate assay (M. A. 
Bioproducts, Walkersville, MD). Con A was purchased from Phar- 
macia (Uppsala,  Sweden).  All glassware used to prepare reagents 
or carry out assays was heated at  180~  for 4 h. 
Induction of GVHD  Single cell suspensions of donor spleen and 
lymph nodes were prepared in HBSS. Recipient B6AF1  animals 
were injected intravenously with 30 or 60  x  106 B6 or 60  x  106 
B6AF1  lymphoid cells. 
Direct Plaque-forming CelI(PFC)Assay.  Spleen cells were assayed 
for the total number of PFCs to SRBC using the technique of Cun- 
ningham and Szenberg (33) as modified in this laboratory (34). 
Cell Lines.  The cell lines  used included L5178Y, a DBA/2- 
derived lymphoma; L929, a C3H/HeN-derived fibrosarcoma; 3T6, 
a Swiss mouse embryo-derived fibroblast line;  YAC-1, an A/Sn- 
derived lymphoma; and MDW4, a DBA/2-derived tumor cell line. 
Cultures were maintained in RPMI 1640 plus 5-10% FCS at 37~ 
in a 5%  COs/air  atmosphere. All cell lines were free of myco- 
plasma infection as determined by periodic monitoring using inoc- 
ulated 3T6 cultures and 6-mercaptopurine deoxyribose (Bethesda 
Research Laboratories,  Gaithersburg, MD) (35). 
Inte~'eron Su~rnatant.  Mouse Con A supernatant (MCS) was 
prepared as a source of IFN-3~ by culturing 3  x  106 B6AF1 spleen 
cells/ml  for  48  h  (37~  COs/air)  in  RPMI  1640  sup- 
plemented with 10% FCS,  5  x  10 .5 2-ME, and 5/xg/ml Con 
A. The supernatants were collected, filter sterilized,  and frozen 
(-70~  until used. 
Md~ Cytotoxicity Assay.  M~b cytotoxic activity was determined 
as previously described (36).  Peritoneal cells were collected from 
mice injected 3  d  previously with  aged Brewer's thioglycollate 
medium (10% wt/vol) (Difco Laboratories, Inc., Detroit, MI). The 
cells were washed twice and adjusted to 2  x  106 cells/ml in ice- 
cold HBSS  and  100-/~1 aliquots  were plated  into  96-well  flat- 
bottomed microtiter plates (Costar 3596; Rochester Scientific Co., 
Rochester, NY). After a 1.5-h incubation (37~  5% CO2/air) the 
cultures were washed vigorously four times with warm HBSS to 
remove nonadherent cells, the wash medium was removed, and 100 
#1 of assay medium (RPMI 1640 plus 10% FCS plus 10 U peni- 
cillin/ml plus 100/~g streptomycin/ml) either alone or containing 
additional reagents was  added to the adherent monolayers.  The 
monolayers consisted of >95% M~b as determined by morphology, 
Diffquick staining and phagocytosis of latex beads (Sigma Chem- 
ical Co., St. Louis, MO). After a 4-h incubation (37~  5% CO2/ 
air)  104 111In-labeled L5178Y cells in 100/~1 assay medium were 
added to the cultures.  Cells were labeled by adding 10/xCi [mln]- 
Oxine (1 mCi/ml, sp act 10 mCi/#g In) (Amersham, OakviUe, 
Ontario, Canada) to 7.5  x  106 cells in 0.5 ml RPMI 1640 plus 
10% FCS at 22~  for 10 rain, before washing and resuspending 
the cells in assay medium.  After a 48-h incubation (37~  5% 
CO2),  the plates were centrifuged (5 min at 500 g) and 100-/~1 ali- 
quots of supematant  were removed and counted in a gamma counter 
(LKB, Turku, Finland).  The percent specific lysis was calculated 
from six replicates  as follows:  100  x  [(test cpm  -  spontaneous 
cpm)/(total cpm  -  spontaneous cpm)]. Spontaneous release cul- 
tures contained normal M~ monolayers and target cells in assay 
medium only. Total cpm was determined from cultures of 104 la- 
beled target cells in 100 #1 assay medium resumended with 100 
#1 of 4% NP-40 (BDH Chemicals,  Montreal, Quebec, Canada). 
TNF Assay.  Blood samples were collected by the cardiac punc- 
ture of mice under ether anasthesia.  The blood was allowed to clot 
at 4~  overnight and the serum was separated and frozen at - 70~ 
until assayed. Serum TNF activity was determined using an L-929 
cytotoxicity assay (37). Subconfluent monolayers of L-929 cells were 
trypsinized, washed, and 6  x  104 cells/well in RPMI 1640 plus 
10% FCS were plated into 96-well microtiter plates (Costar Data 
Packaging, Cambridge, MA). The cells were allowed to adhere for 
1 h (37~  COs), the superuatant was removed, and 50 #1 of 
RPMI 1640 supplemented with 10% FCS and 2/~g/ml actinomycin 
D  (Sigma Chemical Co.) were added.  Twofold serial dilutions of 
serum samples in 50/zl of RPMI 1640  +  10% FCS were added 
to the cultures and after an 18-h incubation (37~  CO2),  the 
cell viability was determined by the reduction of 3- (4,5-dimethyl- 
thiazol-2-yl)-2,5-diphenyltetrazolium  bromide  (MTT)  (Sigma 
Chemical Co.) (38). MTT product that was reduced during a 4-h 
incubation was solubilized by the addition of 100/A 0.04 N hydro- 
chloride acid in isopropanol followed by 100/A of distilled water. 
Reduced MTT was measured on an EAR 400 AT ELISA phte reader 
(SLT Labinstruments, Salzburg,  Austria) at 570 nm (690 nm refer- 
ence wavelength). The concentration of TNF in samples was de- 
termined from a standard  curve of recombinant murine TNF-c~ 
(Genzyme Corp.). 
Rabbit Anti-routine  TNF-a.  Rabbit anti-murine TNF-cr  was 
generously provided by Dr. Anthony Cerami, Dr. Kirk Manogue, 
and Dr. Barbara Sherry (Laboratory of Medical Biochemistry, The 
Rockefeller University,  New  York)  (25).  The ability of rabbit 
anti-murine TNF-a to inhibit serum TNF activity was determined 
by the addition of 5/~1 of antiserum to L929 cultures before the 
addition of serum samples.  Inhibition of Mq~-mediated cytotox- 
icity was determined by the addition of 5/A of antiserum to M~b 
monolayers 1 h before the addition of L5178Y target cells. Cyto- 
toxic function of IFN-3~ plus LPS-activated M~ was inhibited 98% 
by the antiserum. 
LPS Determination.  The chromogenic limulus amoebocyte ly- 
sate assay, (Whittaker Bioproducts, Inc., Walkersville,  MD) was 
used to assay for serum LPS. Sterile serum samples diluted 1:200 
with pyrogen-free water (Whittaker Bioproducts, Inc.) and fur- 
ther twofold serial dilutions prepared with pyrogen-free water con- 
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reaction product was quantified at 405 nm on an EAR 400 AT 
ELISA plate reader (SLT Labinstruments).  LPS concentrations  in 
samples were interpolated from a LPS standard curve prepared from 
E. coli 0111:B4  (Calbiochem Corp.) diluted in pyrogen-free water 
supplemented  with 0.5%  normal  B6AF1 mouse serum. 
Results 
GVHD-induced Immunosuppression and Mortality.  Non- 
irradiated B6AF1 mice transplanted with either 30 or 60  x 
106 B6 lymphoid cells developed GVHD as characterized by 
the onset of severe immunosuppression.  Spleen cells from ei- 
ther transplanted group failed to produce any significant an- 
tibody response after injection on day 10 with a T  cell-de- 
pendent  antigen,  SRBC (Table 1). 
GVHD-induced mortality was, however, dependent upon 
the number of B6 cells injected. Mortality was first observed 
on day 17 posttransplant.  By day 35 the mortality within 
the group receiving 60  x  106 ceils (acute GVH) was 71%, 
whereas  only 4%  of animals  transplanted  with  30  x  106 
cells (nonlethal  GVH) had died. 
Mc~ Priming during GVHD: LPS-triggered  Expression of Mc~- 
mediated Cytotoxic Activity.  The state of M~b activation was 
examined to determine whether an alteration  in M~b func- 
tion  was  related  to  the  symptoms  characteristic  of acute 
GVHD. Activation ofM~ cytotoxic activity occurs via a two- 
stage process. After exposure to IFN-% M~ are primed and 
are then responsive to a second triggering  signal provided 
by LPS.  It is only after LPS triggering that the primed cells 
become cytotoxic (11). On day 14 after transplantation,  Mqb 
isolated from animals undergoing an acute, lethal GVHD ex- 
pressed cytotoxic activity when incubated with  2.5 ng/ml 
LPS, thus indicating  that  the cells had been primed (Table 
2). Cytotoxic activity against L5178Y target cells appeared 
to be dependent upon the amount of LPS that  the effector 
cells were exposed to. As expected, normal Mq~ were non- 
cytolytic unless incubated with MCS, as a source of IFN-% 
and LPS.  The absence of cytotoxic activity against the NK 
cell-sensitive/macrophage-resistant  tumor cell lines YAC-1 
and MDW4 (36) demonstrated that lytic function was not 
mediated by NK cells  (data not  shown). 
It has been reported previously that IFN-3, and LPS affect 
Mq~ in a synergistic manner such that cells exposed to greater 
concentrations of IFN-3, require less LPS in order to be trig- 
gered (10). The LPS dose-responses of Mq~ from animals un- 
dergoing  acute and nonlethal  GVHD were therefore com- 
pared.  As can be seen in Fig. 1, on day 12 after transplantation, 
the concentration of LPS required for expression of cytotoxic 
activity by M~ from B6AFI mice receiving 60  x  106 B6 
cells was "~100 times lower than that required to trigger a 
similar response in M~ from B6AF1 mice transplanted with 
a nonlethal  dose of 30  x  106 B6 cells.  M~b from Fx mice 
transplanted  with  60  x  106  B6  cells  expressed  maximal 
cytotoxic activity in the presence of 5 ng/ml LPS, whereas 
60 
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Figure 1.  MS cytotoxic activity in response to LPS during acute and 
nonlethal GVHD. Mck-mediated cytotoxic activity was determined against 
nlln-labeled L5178Y target cells in a 48-h assay as described in Materials 
and Methods.  LPS dose-response  of M~ from normal B6AF1 mice (11), 
and from B6AF1 mice 12 d after transplantation  with 60  x  106 B6 lym- 
phoid cells (A) or 30  x  106 B6 lymphoid cells (0). Each value represents 
the mean of six replicates of pooled M~k effector cells. Similar results were 
obtained  in two separate experiments. 
Table  1.  Immunosuppression  and Mortality  during  GVHD 
Total PFC  Mortality (dead/total) 
Donor  Recipient  No.  of cells  to SRBC 
strain  strain  transplanted  per spleen*  7 d*  14 d  35 d 
￿  10 -3 
B6  B6AF1  60  ￿  106  0.05  _+  0.05  0/60  0/60  43/60 
B6  B6AF1  30  x  106  0.1  +  0.06  0/60  0/60  2/60 
B6AF1  B6AF1  60  ￿  106  126.8  •  20.4  0/20  0/20  0/20 
-  B6AF1  -  111.6  _+ 25.6  ND 
* On day  10 after transplantation  representative  experimental  mice from each group were injected with 5  x  10  s SRBC and 4 d later the number 
of PFC from individual  spleens was  determined.  The values presented  represent  the mean  •  SEM determined  from six to nine mice. 
* Days after transplantation. 
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Figure 2.  Inhibition of GVH-primed and LPS-triggered M~ cytotoxic 
activity by anti-murine TNF-c~. M~-mediated cytotoxicity against rain- 
labeled L5178Y target cells was determined in a 48-h assay as described 
in Materials and Methods. M@ were isolated from normal B6AF1 mice 
or B6AF1 mice 14 d after transplantation with 60  x  106 B6 lymphoid 
cells. 5/~1 of normal rabbit serum (NRS) or anti-murine TNF-c~  was added 
1 h before addition of target cells. Results represent the mean percentage 
specific cytotoxicity  _+  SEM from three experiments. 
Table  2.  Activation of M~ Cytotoxic Activity by LPS 
during Acute GVHD 
Treatment in vitro 
Mq~-mediated  specific cytotoxicity 
against L5178Y* 
Normal B6AF1  Acute GVHD  B6AFt* 
Medium  0.5  +  0.9 
LPS  -1.7  _+  0.4 
(2.5 ng/ml) 
LPS  -2.0  _+  3.6 
(50 ng/ml) 
IFN  s  1.6  +_  1.4 
IFN  S 
+  53.0  +  3.3 
LPS 
(2.5  ng/ml) 
3.7  -+  1.3 
30.9  _+  3.8 
55.5  +  4.0 
6.7  +  0.7 
54.3  +  4.2 
500  ng/ml LPS was required to  trigger a  similar response 
in M~ from Ft mice transplanted with 30  x  106 B6 cells. 
The results clearly indicate that M~b priming occurred to a 
greater extent  during  acute GVHD.  M~b  from  normal  F1 
animals expressed only minimal cytotoxic function even in 
the presence of 5,000  ng/ml LPS. 
M~b-mediated killing of L5178Y target cells has been shown 
* X  +  SEM of three experiments. M~-mediated cytotoxicity was de- 
termined  against rain-labeled  L5178Y target  cells in a 48-h assay as 
described in Materials and Methods. 
* B6AF1 animals were transplanted with 60  x  106 B6 cells and their 
peritoneal M~ were collected and used on day 14 posttransplant. 
s IFN from mouse Con A supernatant was added at a concentration of 
200/zl/ml. Activation of normal Mq~-mediated cytotoxic function by 
MCS, in combination with LPS, was completely inhibited by the addi- 
tion of R46A2 mAb against murine IFN-% 
Table  3.  Lethal  Effect of LPS during GVHD 
Donor  Recipient  No.  of cells 
strain  strain  transplanted 
Mortality within 36 h  of 
injection (dead/total) 
LPS*  7 d*  14 d 
B6  B6AF1  60  ￿  106 
B6  B6AF1  30  x  106 
B6AF1  B6AF1  60  x  106 
-  B6AF1  - 
~g 
10  24/24  24/24 
2  1/12  13/22 
0  0/12  0/12 
10  6/24  7/24 
2  ND  1/24 
0  0/12  0/12 
10  0/12  0/12 
100  0/6  0/6 
10  0/12  0/12 
* Animals were injected intravenously with LPS in 0.2 ml PBS or PBS alone. 
Days after transplantation. 
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by M~ after activation with IFN-7 and LPS (12). As is demon- 
strated in Fig. 2, addition of anti-murine TNF-ot to the M~ 
cytotoxicity assay completely inhibited the LPS-triggered cyto- 
lytic  activity  of M~  primed  during  the  acute  GVHD, 
confirming  that  it was mediated by TNF-ot. 
Sensitivity  to LPS is Related  to the Severity of the GVHI~ 
Since we demonstrated in vitro that the degree of M~ priming 
was related to the severity of the GVHD, we next investigated 
the in vivo effect of LPS. The lethal effects of LPS were related 
to the length  of time after transplantation,  the number of 
lymphoid cells transplanted,  and the dose of LPS.  In acute 
GVH-reactive mice, intravenous injection of 10/zg of LPS, 
either 7 or 14 d after 60  x  106 B6 cells were transplanted, 
resulted in the death of 100%  of the animals  within  36 h 
(Table 3). The animals characteristically developed a hunched 
posture, piloerection, and severe diarrhea within 2-6 h after 
LPS injection.  A  dose of 2/~g of LPS on day 7 resulted in 
1 of 12 animals dying, whereas greater than 50% died, given 
the same dose on day 14.  LPS also had a significant effect 
on animals transplanted with 30  x  106 B6 cells. Although 
the injection of 2 #g on day 14 resulted in the death of only 
1 of 24 animals,  ~25%  died after injection with  10 #g of 
LPS either 7 or 14 d posttransplant.  Mortality was not ob- 
served in  normal  B6AF1  mice  injected  with  either  10 or 
100/~g  of LPS (Table  3). 
TNF-ot Production during GVHD: Triggered  Release by LPS. 
To determine whether TNF was produced in response to LPS 
and also to induce maximal TNF release,  animals were in- 
Table  5.  Inhibition of LPS-induced Serum TNF from 
Acute GVHD Mice by Anti-murine  TNF-a 
Serum TNF activity* 
Day injected 
with LPS~  No. of mice  Anti-TNF-cr s  Control~ 
U/ral  x  10-3 
7  5  (0.20  18.4  _+  8.3 
14  5  (0.20  63.3  _+  9.7 
" X  -+  SEM from individually  determined  samples. TNF activity was 
determined using the MTT dye reduction assay on actinomycin  D-treat- 
ed L929 cells as described  in Materials  and  Methods. 
* B6AFI animals transplanted  with 60  x  106 B6 cells were injected in- 
travenously  with 25/~g LPS in 0.2 ml PBS on the day posttransplant 
indicated.  2 h later blood samples were collected as described in Materi- 
als and Methods. 
$ 5/zl of rabbit  anti-murine TNF-ot was added  to TNF assay cultures 
immediately before addition of serum  samples. 
II 5/zl of normal rabbit  serum (NRS) was added to the TNF assay cul- 
tures.  NRS did not itself have any cytotoxic activity against L929 cells. 
jected intravenously with 25/zg of LPS and bled 2 h  later 
(Table 4). In acute GVH-reactive mice, injection of LPS 7 d 
after transplantation  induced  serum  TNF levels  of 14,759 
U/ml.  On day 14,  LPS-triggered  serum  TNF levels  were 
'~3.5-fold greater.  Mice receiving a nonlethal transplant  of 
30  x  106 B6 ceils produced significantly lower concentra- 
Table  4.  LPS-triggered Production of Serum  TNF during GVHD 
7d*  14d 
Donor  Recipient  No.  of 
strain  strain  cells  LPS*  No.  of mice  TNFS  No.  of mice  TNFS 
U/ml  U/ml 
x  10 -~  ￿  I0 -3 
B6  B6AF1  60  x  106  +  5  14.8  _+  7.411  9  52.9  _+ 8.81 
-  7  ~0.02  10  ~0.02 
B6  B6AF1  30  x  106  +  6  1.3  _+ 0.5  10  12.0  ___ 5.9 
-  4  (0.02  5  (0.02 
B6AF1  B6AF~  60  x  106  +  ND  6  0.08  •  0.08 
-  ND  9  ~0.02 
-  B6AF1  -  +  10  0.5  _+ 0.3  10  ~0.02 
-  5  ~0.02  10  ~0.02 
* Days after  transplantation. 
* Animals were injected intravenously  with 25/zg LPS in 0.2 ml PBS or PBS alone.  2 h later blood samples were collected as described in Materials 
and  Methods. 
S ~  _+  SEM of individually  determined  samples. TNF activity was determined using the MTT dye reduction assay on actinomycin  D-treated L929 
cells as described  in Materials  and  Methods. 
II p  ~0.005  on day  7 as compared  with day  14 after  transplantation  with 60  x  106 B6 cells. 
I p  <0.001  on day 14 after  receiving  60  x  106 B6 cells as compared  with day  14 after  receiving  30  x  106 B6 cells. 
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of Acute GVHD Reactive Mice 
No. of 
Days  Positive  animals 
posttransplant*  Mortality  for LPSt  tested  LPS 
pg/mlS 
~o  ~o  x  I0 -3 
10  0  0  8  <0.12 
12  0  0  8  <0.12 
14  0  0  8  <0.12 
16  14.9  40  15  2.2  -+  1.5 
* 142 B6AF1 mice were transplanted with 60 x  106 B6 lymphoid cells. 
Animals were randomly selected for testing on the day posttransplant 
indicated. 
*  Serum samples were collected aseptically  and tested for LPS as described 
in Materials and Methods. 
S X  _+ SEM of LPS-positive samples. 
tions of serum TNF. As is shown in Table 4, neither normal 
nor  syngeneic  transplanted  B6AF1  animals  produced  sig- 
nificant amounts of TNF after LPS injection. Spontaneously 
released TNF could not be detected in the serum of any of 
the GVH-reactive animals injected with PBS. The TNF in 
the sera of acute GVH-reactive mice injected with LPS was 
determined to be entirely TNF-c~, as its activity was com- 
pletely  inhibited  by  the  addition  of anti-murine  TNF-c~ 
(Table  5). 
Detection of  Endogenous Serum LPS during Acute GVHD  To 
determine whether endogenous LPS was present in B6AF1 
mice during acute GVHD, serum samples were assayed for 
LPS at various times after transplantation with 60  x  106 B6 
lymphoid cells  (Table  6).  In  a large group  of transplanted 
animals,  the first  death occurred on day 16 posttransplant. 
LPS was detected in the serum of 40% of randomly selected 
animals on day 16, but not at any of the prior time points. 
By day 18 posttransplant,  2 d  after LPS could be detected 
in the serum, mortality increased to 49%. LPS bound to li- 
poproteins (39) or to LPS-binding protein (40) in the serum 
may be much less active than unbound LPS in the limulus 
assay, therefore, the results presented are perhaps a conserva- 
tive estimate of the actual levels  of serum LPS. 
Discussion 
Our results demonstrate that M~b are primed during the 
course of the GVHD and that  the level of M~ priming  is 
greater in mice undergoing acute lethal as opposed to non- 
lethal GVHD. As a consequence of M~ priming,  normally 
insignificant amounts of LPS trigger TNF-o~ release into the 
serum leading to death of acute GVH-reactive animals and 
in vitro result in the expression of Mck-mediated tumor cy- 
totoxicity. Coincident with the time of onset of mortality, 
endogenous LPS can be detected in the serum of acute GVH- 
reactive animals.  The results demonstrate  that  MO can act 
as a source of TNF-ol  during  GVHD. 
IFN-c~,  IFN-3, and IFN-3' can activate or prime M~k and 
there is evidence of production of all three types of IFN during 
GVHD (14,  15, 41).  The greatest priming effect on MO is 
known to be mediated by IFN-y (42).  MO were found to 
be primed to a much greater extent during the acute as com- 
pared with the nonlethal GVHD (Table 2 and Fig.  1). The 
importance of IFN-y within the network of cellular and cy- 
tokine interactions that occurs during GVHD is demonstrated 
by the reduction in the severity of GVHD-induced intestinal 
lesions after anti-IFN-3/treatment  (16). 
Priming of normal M~k results in a large reduction in the 
amount of LPS needed to trigger both TNF-ol release  and 
M~b-mediated cytotoxic function  (10-12,  28).  F1 mice in- 
jected with 60  x  106 parental strain  cells were especially sen- 
sitive to LPS since all of the animals died within 36 h of in- 
jection  of  10  gg  LPS  whereas  normal  F1  animals  were 
resistant to 100 #g LPS (Table 3). The terminal symptoms 
characteristic  of acute GVHD occurred soon after intrave- 
nous injection of 10 #g of LPS into animals transplanted  7 
or 14 d previously with 60  x  106 B6 cells. The symptoms, 
including a hunched posture, piloerection, and diarrhea, are 
also characteristic  of animals  injected with  TNF-o~ (43). 
Significant amounts of TNF-o~ were found in the serum 
of animals undergoing GVHD 2 h after an intravenous in- 
jection of LPS (Table 4). The amount of serum TNF-ot was 
related to the number of donor cells transplanted  and time 
posttransplant.  Without the administration of LPS, TNF-o~ 
could not be detected in the serum of any of the GVH-reactive 
animals examined. However, a reduction in mortality and ep- 
ithelial lesions does occur in GVH-reactive mice treated with 
anti-TNF-c~,  despite the absence of detectable serum TNF 
(29). The absence of circulating TNF-c~ may be due to rapid 
binding  of TNF-o~ by liver,  kidney,  skin,  and  gastrointes- 
tinal tissues resulting in a short serum half-life  (44, 45). In 
human  allogeneic bone marrow  recipients,  TNF-c~ can be 
detected in the serum (30) and does appear to be associated 
with  GVHD (31,  32). 
Although priming  of M4) facilitates  their ability to pro- 
duce TNF-ol, LPS is required to trigger TNF-ot release from 
MO (12). Endogenous LPS was found in the serum of animals 
undergoing acute GVHD and the time of detection was coin- 
cident with the onset of mortality (Table 6). Translocation 
of Gram-negative bacteria across  the damaged gastrointes- 
tinal epithelium  and into the portal circulation may be the 
prime source of LPS during GVHD. Increased bacterial trans- 
location has been demonstrated in immunosuppressed animals 
(46). Thus the immunosuppression and lesions of the intes- 
tinal epithelium that are characteristic of GVHD would pro- 
mote the translocation  process. Augmentation of MO-mediated 
bactericidal and phagocytic activity during GVHD (8, 9) pre- 
vents the occurrence of active infections during  the period 
of severe immunosuppression associated with GVHD, yet at 
the same time, results in the presence of LPS in the serum. 
Under normal circumstances, LPS is rapidly taken up in the 
liver (47), however, the appearance of LPS in the serum on 
day 16 posttransplant suggests that the liver's ability to scav- 
410  Macrophages  as Erector Cells during Acute Graft-Versus-Host Disease enge LPS has become saturated. During GVHD, interaction 
between LPS and primed Mq~ that accumulate in a number 
of organs, including the liver and spleen (4, 48), would pro- 
vide a ready source of TNF-c~. Although T cells, NK cells, 
and mast cells can produce TNF-cr (49-51), M~ are a prin- 
cipal source of TNF-c~ and the only cell type known to re- 
lease the cytokine in response to LPS. 
The possibility that LPS may mediate some of the symp- 
toms characteristic of GVHD has been suggested by a number 
of observations. The hepatic lesions that develop  in mice during 
experimental endotoxemia are strikingly similar to those that 
occur during GVHD (52). A significant reduction in the in- 
cidence and severity of GVHD can be obtained through gas- 
trointestinal decontamination, germ-free conditions, and pro- 
tective laminar flow environments (19-21). In (C57BL  x 
CBA)F1 mice transplanted  with CBA lymphoid cells two 
mechanisms, one associated with LPS and the other LPS in- 
dependent, have  been demonstrated to be involved in GVHD- 
associated tissue injury (53). Furthermore, passive immuni- 
zation of mice with an antiserum to that portion of the LPS 
molecule  common to all forms of LPS improved survival after 
acute GVHD (54). 
It appears that at least three phases are involved in the de- 
velopment of acute GVHD. The initial afferent phase that 
occurs during the lymphoproliferative response to alloantigen 
involves the excessive  production of  cytokines, including IFN-y 
(13-15) produced by CD4 +, CD8 +, and/or NK cells (55). 
As a result of the interaction  with released cytokines, NK 
or NK-like cells are activated and priming of M~ occurs. The 
second phase involves an initial injury to epithelial tissues, 
including the epithelium of the gastrointestinal  tract, which 
appears to be mediated by activated NK or NK-like cells 
(56-59).  In addition,  primed Mq~ may produce TNF-c~ as 
a result of interaction with glycosylated proteins released from 
damaged tissue and thus also contribute to the initial tissue 
destruction (60). In the third phase, as a result of injury to 
the gut epithelium, increasing amounts of Gram-negative bac- 
teria enter the portal circulation and are rapidly taken up and 
killed by fixed Mq~ in the liver (i.e., Kupffer cells) and splenic 
M~. Bacterial-derived LPS from the killed Gram-negative 
bacteria then triggers the release of nonphysiologic amounts 
of TNF-c~ from primed M~6 resulting in cachexia, further 
tissue injury,  shock, and death of the transplant  recipient. 
The three phases therefore include an afferent phase that leads 
to the activation of two different effector cells, NK or NK- 
like cells and Mq~, which in turn mediate the two efferent 
phases of tissue damage. The evidence  supportive of the mech- 
anisms described here includes the prevention  of GVHD- 
related pathologic lesions and immunosuppression after treat- 
ment with anti-IFN-7 (16, 61), or after elimination of NK 
or NK-like cells (56-59), prevention of pathologic lesions by 
treatment with anti-TNF-o~ (29), and reduction of tissue in- 
jury through bacterial decontamination (19-21, 53).. 
The consequences of Mck priming can be beneficial or 
detrimental depending upon the degree to which the cells 
have been primed. In the case of nonlethal GVHD, relatively 
low levels of M~ priming and the ability to produce TNF-c~ 
were observed. TNF-ot can augment host resistance to bac- 
terial,  viral,  and fungal infections (62-64)  and therefore a 
moderate degree of  M~ priming is beneficial during GVHD. 
In the present study animals with nonlethal GVHD survived 
for >6 mo in a conventional housing facility despite severe 
prolonged immunosuppression. TNF-o~ production by primed 
M~b during nonlethal GVHD may also be the underlying 
mechanism of the graft-versus-leukemia effect which results 
in a decreased incidence of leukemic relapse in bone marrow 
transplant recipients with low-grade GVHD. Conversely, ex- 
cessive priming of Mq~ resulting in overproduction of TNF-oL 
can lead to progressive GVHD and death of the transplant 
recipient. 
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